trastuzumab cardiotoxicity in destiny-breast04 trial
Published 2 years ago • 49 plays • Length 8:49Download video MP4
Download video MP3
Similar videos
-
5:02
reflections on the destiny-breast04 trial | patricia lorusso
-
7:06
long-term risk of heart failure with trastuzumab
-
6:33
detailed safety analysis from the destiny-breast04 trial
-
0:56
destiny-breast04: t-dxd for patients with her2-low mbc
-
1:47
safe: cardiotoxicity prevention in breast cancer treated with anthracyclines and/or trastuzumab
-
7:23
anthracycline cardiotoxicity
-
1:08
destiny-breast04: a ground-breaking trial in her2-low breast cancer
-
3:36
trastuzumab deruxtecan in patients with breast cancer and brain metastases in destiny-breast01
-
2:40
destiny-gastric02: 2l t-dxd in her2 gastric cancers
-
2:01
beyond anthracyclines and trastuzumab: cardiotoxicity of novel agents
-
2:58
updated analysis of destiny-gastric02: t-dxd in her2 gej cancer who progressed with trastuzumab
-
4:35
a multi-histology basket trial of ado-trastuzumab emtansine in patients with her2 amplified cancers
-
2:43
margetuximab for the treatment of her2-positive breast cancer
-
1:16
her2-low expression in breast cancer
-
2:06
antibody-drug conjugates for her2-low disease: 2023 ku breast cancer year in review
-
1:11
32 month follow-up of mountaineer: tucatinib and trastuzumab in her2 mcrc
-
2:00
neratinib after trastuzumab-based adjuvant therapy in her 2 positive breast cancer (extenet)
-
1:45
dr. piccart on the success of trastuzumab